خانه › سرطان متاستاتیک › ایلینوی › Chicago
آزمایش‌های بالینی سرطان متاستاتیک در Chicago، IL
45 مطالعه برای سرطان متاستاتیک در مراکز Chicago (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
در حال جذب شرکت‌کنندهمرحله 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- و 3 مورد دیگر
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of Chicago Hospital, Chicago
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
در حال جذب شرکت‌کنندهمرحله 3
- City of Hope, Chicago
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
در حال جذب شرکت‌کنندهمرحله 1
- Northwestern University, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
در حال جذب شرکت‌کنندهمرحله 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Illinois Cancer Specialists, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
در حال جذب شرکت‌کنندهمرحله 3
- Research Site, Chicago
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Chicago, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
در حال جذب شرکت‌کنندهمرحله 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
در حال جذب شرکت‌کنندهمرحله 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
CREO - Microwave Ablation Feasibility Study
در حال جذب شرکت‌کننده
- Rush University Medical Center, Chicago
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
در حال جذب شرکت‌کنندهمرحله 1
- Northwestern University ( Site 0101), Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Northwestern University, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
در حال جذب شرکت‌کنندهمرحله 3
- Northwestern University, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
در حال جذب شرکت‌کنندهمرحله 1/2
- Northwestern University, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
در حال جذب شرکت‌کنندهمرحله 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 2
- Research Site, Chicago
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
در حال جذب شرکت‌کنندهمرحله 1
- University of Chicago Comprehensive Cancer Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
در حال جذب شرکت‌کنندهمرحله 3
- Research Site, Chicago
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- The University of Chicago Medicine, Chicago
A Study of PYX-201 in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of Chicago Medicine, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
در حال جذب شرکت‌کنندهمرحله 1
- The University of Chicago Medical Center (UCMC), Chicago
REMASTer: REcurrent Brain Metastases After SRS Trial
در حال جذب شرکت‌کننده
- University of Chicago, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
در حال جذب شرکت‌کنندهمرحله 3
- Northwestern University, Chicago
CT-95 in Advanced Cancers Associated With Mesothelin Expression
در حال جذب شرکت‌کنندهمرحله 1
- Context Investigational Site, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
در حال جذب شرکت‌کنندهمرحله 2
- Northwestern University, Chicago
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
در حال جذب شرکت‌کنندهمرحله 3
- University of Illinois Cancer Center, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
در حال جذب شرکت‌کنندهمرحله 2/3
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
در حال جذب شرکت‌کنندهمرحله 1
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- John H Stroger Jr Hospital of Cook County, Chicago
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
در حال جذب شرکت‌کنندهمرحله 1
- University of Illinois at Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
در حال جذب شرکت‌کنندهمرحله 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
در حال جذب شرکت‌کنندهمرحله 3
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
در حال جذب شرکت‌کنندهمرحله 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Massive Bio SYNERGY-AI site, Chicago
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
در حال جذب شرکت‌کنندهمرحله 1
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
در حال جذب شرکت‌کنندهمرحله 1
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
در حال جذب شرکت‌کنندهمرحله 1
- University of Chicago, Chicago
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Northwestern University, Chicago
آزمایش‌های سرطان متاستاتیک در سایر شهرها
- Houston, TX104 مطالعه
- New York City, NY93 مطالعه
- Nashville, TN70 مطالعه
- Boston, MA63 مطالعه
- Los Angeles, CA57 مطالعه
- St. Louis, MO54 مطالعه
- Arlington, VA53 مطالعه
- Philadelphia, PA46 مطالعه
- San Antonio, TX44 مطالعه
- Washington, DC43 مطالعه
- Dallas, TX42 مطالعه
- Seattle, WA39 مطالعه
سایر مطالعات در Chicago
- سرطان ریه غیرسلول کوچک61 مطالعه
- سرطان پستان58 مطالعه
- سرطان (همه انواع)51 مطالعه
- سرطان پروستات45 مطالعه
- چاقی41 مطالعه
- سرطان ریه41 مطالعه
- سرطان تخمدان36 مطالعه
- سکته مغزی34 مطالعه
- سرطان کولورکتال33 مطالعه
- نارسایی قلبی31 مطالعه
- اضافه وزن28 مطالعه
- کارسینوم سلول سنگفرشی سر و گردن26 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 5 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.